Skip to main content

Table 1 Baseline RA patient’ characteristics

From: Successful long-term remission through tapering tocilizumab infusions: a single-center prospective study

 

All patients

(n = 13)

Age, mean (SD), years; (min-max)

48.23 ± 14.5, (21–67)

Female, n (%)

9 (69.2%)

Disease duration, mean (SD), years; (min-max)

11.46 ± 9.44; (2–36)

TCZ exposure before tapering, months (SD); (min-max)

18.38 ± 7.34; (5–29)

Remission achievement delay, months (SD); (min-max)

2.38 ± 2.63; (0–8)

Remission duration, months (SD); (min-max)

7.53 ± 6.21; (3–24)

RF positive, n (%)

7 (53.8%)

ACPA positive, n (%)

7 (53.8%)

Erosive status, n (%)

10 (76.9%)

Previous number of sDMARDs; (min-max)

2.15 ± 0.9; (1–4)

Previous number of bDMARDs; (min-max)

1.7 ± 1.18; (0–3)

Swollen joint count; (min-max)

0.08 ± 0.27; (0–1)

Tender joint count; (min-max)

3.14 ± 3.4; (0–10)

Hyperhemia at Doppler

2 (15.4%)

Number of patients with active synovitis

7 (53.8%)

Number of active synovitis

 Hands

14

 Feet

5

Concomitant therapy

 MTX, n (%)

6 (42.9%)

 LEF, n (%)

3 (21.4%)

DAS28; mean (SD); (min-max)

1.65 ± 0.93; (0–2.6)

ESR, mm/h; mean (SD); (min-max)

7 ± 9.12; (1–27)

CRP, mg/L, mean (SD); (min-max)

2.21 ± 2.34; (0.2–7.4)

TCZ plasma level, mg/L; mean (SD); (min-max)

7.35 ± 6.41; (0–16)

ADAb positivity

0

  1. RA rheumatic arthritis, SD standard deviation, n number, TCZ tocilizumab, RF rheumatoid factor, ACPA anti-citrullinated peptide antibodies, MTX methotrexate, LEF leflunomide, DAS28 Disease Activity Score in 28 joints, ESR erythrocyte sedimentation rate, CRP C-reactive protein, ADAb antidrug antibodies